CYTO - רווח נקי למניה (EPS TTM) Altamira Therapeutics Ltd

Altamira Therapeutics (CYTO) maintains a stable image in the biotech sector based on confidence in its RNA delivery system. Growth is driven by licensing deals and the integration of Peptide+ into partner formulas. The rolling annual earnings per share on this GURU.Markets chart confirms this, where 1.81 shows the current value of the metric. Resilience to crises is guaranteed by the demand for allergy medications across any market cycle.

Altamira Therapeutics (CYTO) maintains a strong position in the R&D segment through the development of peptide nanoparticles for RNA delivery. This indicator measures net income allocated per share, excluding the impact of capital structure. Investors utilize this balance to assess the real efficiency of the business prior to licensing deals with pharma behemoths. The positive trend confirms the issuer's financial stability. The annual net income per share price action reflects the company's reaction to market shocks.